Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Expands Merck Drug Target Pact

NEW YORK (GenomeWeb News) – Galapagos said today that it has expanded a preclinical development agreement to discover, screen, and validate drug targets that Merck will develop and take to market.

The agreement, which could be worth as much as €400 million ($596 million), adds atherosclerosis drug targets to an earlier one that covered targets for obesity and diabetes.

This pact gives Merck an exclusive option to license each candidate for clinical development and worldwide commercialization, and it gives Galapagos the right to conduct Phase I clinical studies and to develop and market compounds that Merck does not option.

The initial agreement, sealed in January 2009, included potential milestone payments of up to €170 million for Galapagos, which also may be eligible for royalties from commercialization of products.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.